Meet some of the companies joining us in Singapore
The HealthXL Global Gathering in Singapore on November 3rd will bring together leading international Investors, Clinicians, Entrepreneurs, and C-Level executives to discuss topics such as Big Data & Blockchain, Connected Health, New Care Models and their impact in bringing about change within digital health.
Our events are an exciting opportunity for us to bring together the leaders from across the HealthXL community to come together under one roof. The events expose the members to the best external innovation within a particular focus topic, clinical opinions on current practices, and global healthcare connections. In addition, the events highlight opportunities to collaborate on specific projects with other leading global brands and innovative companies. In Singapore, the focus will be around Big Data & Blockchain, Connected Health and New Care Models.
IBM Healthcare solutions help organizations build sustainable healthcare systems, improve care and outcomes, and engage individuals in their own care.
Bupa is a global health and care company serving 32 million customers in 190 countries
GSK is one of the worlds largest pharmaceutical companies. GSK is dedicated to improving the quality of human life by enabling people to do more, feel better, live longer.
Merck is one of the worlds largest international developer, manufacturer and distributor of pharmaceuticals. Their core product categories include diabetes, cancer, vaccines and hospital acute care.
Philips Respironics is the leading provider of innovative solutions for the global sleep and respiratory markets.
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
EY is a global leader in assurance, tax, transaction and advisory services. The insights and services they deliver help build trust and confidence in the capital markets and in economies the world over.
Johnson & Johnson
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer. Johnson & Johnson are one of the worlds largest pharmaceutical manufacturers.
ResMed changes lives with every breath by building products that treat sleep apnea, COPD and other chronic respiratory diseases.
In our next post, we will be taking a look at our speakers who will be joining us in Singapore. They will be speaking on topics such as Big Data & Blockchain, Connected Health, New Care Models and their impact in bringing about change within digital health.
Story snapshot: This month, Biofourmis announced the acquisition of Biovotion. The acquisition includes all of Biovotion's assets, including the Everion biosensor and 60+ global patents, covering most of the wearable and sensor technology that exists for the arm or hand, as well as Biovotion's staff, partners, and clients. On top of this, Biofourmis have just announced a partnership with Novartis on the use of a predictive analytics platform (BiovitalsHF) in combination with the Everion sensor to monitor heart failure patients.
Why is it notable?
Biofourmis have now established themselves as a very strong contender in the digital therapeutics and predictive analytics market, combining their data platform with a well established clinical-grade device from Biovotion. Biofourmis (after their inception in Cambridge) did most of their early work in Singapore, and those roots may give them a stronger foothold in Asia going forward given the relationships they've built.
This acquisition of Biovotion is actually Biofourmis’ second acquisition in two months. In October, Biofourmis acquired India-based Hashtaag (an information technology and services company focused on software and product development). This strategic acquisition of a company that Biofourmis previously worked with as a vendor was focused on acquiring the 30-person Hashtaag team and its related expertise to accelerate Biofourmis’ product development - specifically for pain and oncology.
The recent partnership with Novartis is also notable given the work Novartis are doing in relation to their heart failure drug ENTRESTO. So now, patients’ doctors are not only prescribing ENTRESTO—they are also prescribing digital therapeutics to optimize the drug therapy and to better target dosages, with a goal of better patient outcomes. Interestingly, Novartis also recently announced a partnership in the Asian market to develop WeChat assistant 'AI Nurse' for heart failure patients.
Biofourmis and Biovotion have been long standing industry partners - Could we see a similar trend of acquisition by data analytics platforms of partner device companies in future? Just a few weeks ago we say Tech Giant Google acquiring wearable device maker fitbit, hammering home a recognition of the value for wearables as a mode to capture digital biomarkers.
On top of all of this, Biofourmis deal with Novartis is one of the largest commercial digital therapeutics projects to date. The project will begin with initial roll-out in South East Asia, with plans to expand into more geographies in future. We are excited to see where this partnership goes and if it will catalyse more commercial DTx/Pharma partnerships, particularly given the recent news of the Pear/Sandoz breakup which highlighted the vast unknowns that still exist around DTx commercialisation.
Story snapshot: I am sure you heard - Google has bought Fitbit for a whopping $2.1 billion. We debated writing about it this week because the healthcare implications are not that obvious yet. But then again, this is Google, and the healthcare participation will certainly follow. So, here goes.
Why is it notable?
AI, software and hardware - Fitbit has already figured out these bits.
Google is no stranger to healthcare - since it raised its first fund in 2009, it has backed nearly 60 health-related enterprises; Verily Life Sciences founded in 2015; Alphabet has filed for 186 patents related to the healthcare field, ex-Geisinger Health System CEO as the VP etc. So Fitbit may well be another play in this direction.
Fitbits’ 28 million users could literally be a predictive analytics game changer in serving personalized health recommendations and interventions, as long as this data is not used to serve us back Google ads!
Fitbit has already worked off Google Cloud for Healthcare APIs with the promise of sharing fitness and health data easily and safely. This acquisition may imply further strengthening of this promise.
Story snapshot: Pear Therapeutics has entered a partnership with Ironwood Pharmaceuticals to bring to market prescription digital therapeutics (PDT) for gastrointestinal (GI)indications.
Why is it notable?
GI indications like Irritable Bowel Syndrome are quite amenable to a 'digital' intervention in the form of supporting nutrition, symptom tracking, etc. So it is perhaps an easier intervention. The same cannot be said about Inflammatory Bowel Disease where the medication cannot be replaced by these PDTs.
Noise. DTx have been making so much noise in the last while. The reality is that we are unclear on what GI indications or products this partnership is going to bring out.
Comes at the back of the end of Pear's partnership with Sandoz for substance use disorder treating PDTs. So, it looks like Pharma partnerships are still going strong for digital therapeutics.
We cannot say we know anything more than we did last month or the month before, which is challenging as more pharmaceutical companies and start ups try to crack the business model and go to market strategy for these types of partnerships.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
Static and dynamic content editing
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
How to customize formatting for each rich text
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
Every week top healthcare executives read our blog
Subscribe to get the inside track on digital health
Thank you! You will receive our newsletter every Sunday and occasional updates on new reports & events. You can unsubscribe at any time.
Oops! Something went wrong while submitting the form.